00:00Doctor Caramuscio, why should prevention be recognized in all respects as the first and most advanced form of
00:06innovation?
00:07In a context like the one we live in, where we are seeing an ageing population and the data tells us that
00:13the population will get older and older,
00:15Prevention becomes essential to allow innovation to express its full potential.
00:23Therefore prevention and innovation are two complementary levers to offer and develop value for both the patient and the
00:31system.
00:32No drug will be able to express its maximum therapeutic value either for the patient or for the system if it arrives
00:39too late.
00:41There are therapeutic areas such as chronic kidney disease which is a silent degenerative pathology in which it is
00:48it is essential to intercept patients in an early stage of pathology.
00:52To allow the drugs currently available to delay the progression of the disease and to allow the drugs that will arrive and
01:00which even promise to block the progression of the disease
01:04to act on a patient who still has preserved renal function, avoiding dialysis and transplant.
01:12With a very important impact on the quality of life of patients and caregivers and with a fundamental impact on the system
01:19health care
01:19because dialysis today costs around 2.5 billion a year.
01:24Well, in a system like this it is fundamental, as I said before, to consider innovation and prevention as two levers that act
01:33in a unique way to generate value.
01:36As pharmaceutical companies and as Otsuka we are absolutely supportive of creating screening activities or programs together.
01:50to institutions and scientific societies.
Commenti